



Biotechnology Company with Assets in Drug Testing

Mr Howard Digby
Dr Anton Uvarov
20 November 2013



Important information

This presentation has been prepared by Sun Biomedical Limited. ("Sun Biomedical" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Sun Biomedical, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Sun Biomedical and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Sun Biomedical is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Sun Biomedical securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Sun Biomedical, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Sun Biomedical does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Sun Biomedical to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Sun Biomedical will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Sun Biomedical and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).



Sun Biomedical Board and Management

Executive Chairman: **Mr Howard Digby**

Proposed Director:
(from 20 November 2013) **Dr Anton Uvarov**

Non-Executive Director: **Mr Evan Cross**

Non-Executive Director &
Company Secretary: **Mr Peter Webse**

- A tight team with extensive industry and public company experience



Sun Biomedical Capital Structure

ASX:	SBN
Share Price (19 Nov 13):	0.011
Market Cap (19 Nov 13):	\$3.6m
Shares on Issue:	331m
Options:	20.8m
Cash (end Oct 13):	\$1.56m
Number of shareholders:	1511
Shareholder Distribution	Top 20 hold > 60%

Investment Highlights

- Multiple-drug testing devices (acquired June 2007)
- Invested \$8m on the product portfolio over 6 years
- Strong IP portfolio anchored by novel collection mechanism and testing strip design
- US “Drugs of abuse” testing market expected to reach \$2.0 billion in 2014*
- Clear strategy to market with strong margins


* Source BBC research



Company Strategy

- Exploit value in existing drug delivery technology and product portfolio.
 - Determine items with competitive advantage and unique features
 - Determine steps to market including
 - Product enhancements
 - Alternative manufacturing options
 - Channel
 - Licensing
- Reviewing additional bolt-on acquisitions in the biotechnology industry


Market opportunity



- Global Drugs of Abuse (DOA) testing market size and forecasts (Source: BCC Research)
 - The global market for DOA testing during past 5 years showed compound annual growth rate (CAGR) of 4.6%. It is expected to reach \$2.6 billion in 2014.
 - The U.S. testing market segment generated the largest share of revenues in the previous 5 years and is expected to reach \$2.0 billion in 2014, with a CAGR of 5.2%.
 - The European Union had the second largest market segment and is expected to reach \$446 million in 2014, with a CAGR of 2.9%.

Technology Overview

- Lateral Flow Immunoassay – how it works



Sun Biomedical Product Pipeline

**Product
Design**

**Prototype
Validation**

**Manufacturing
(Market Ready)**

**Product
launch**

Oraline® Family - Workplace and personal saliva testing solutions

Oraline® (standard Strip)



Oraline®(Patented Oraline Strip)



Oraline® (6 Plus drug device)



Visualine® Family – Urine and Saliva testing with customized strip combination

Visualine®MultiDip Panel



Visualine® Cassette




Oraline[®] Family

- Unique cup collection mechanism
- Unmet market need
- IP with opportunities for further enhancement
 - Color coded Test Strip (Unique “before” markings showing that the test is valid)
 - Lateral Flow Device (useful as the basis for a two strip device testing 6 plus drugs at the same time)



Oraline[®] - R&D Progress

- Testing housing and strip modifications to improve test quality and resolution.



- Final prototyping stage
- Establishing manufacturing costs
- Potential third party licensing

Oraline® Family: Business development

Market analysis including price points	60% complete
Design enhancements (housing and strip)	80% complete
Prototype testing	December
New strip manufacturer	January
Housing manufacturer	January
Distribution agreements and licensing to third parties	February and March
Product Launch	March, April

VisuaLine®MultiDip Panel

- VisuaLine® Multi Dip Drug Screens are extremely accurate, customizable immunoassay screens designed to detect the presence of any combination of the following illicit drugs and their metabolites in human urine:
 - *Amphetamines (AMP), Barbiturates (BAR), Benzodiazepines (BZD), Cannabinoids/Marijuana (THC), Cocaine (COC), Ketamine (KET), Methadone (MTD), Methamphetamines (MET), Morphine/Opiates/Heroin (MOR), Oxycodone (OXD), Phencyclidine (PCP), Propoxyphene (PPX), Tricyclic Antidepressants (TCA)*
- VisuaLine® requires only 5 minute incubation (rapid urine test)



* Product in development

Sun Biomedical – Intellectual Property

US Patent Number	Description
6046058	Colour Coded Test Strip
5962336	Multi-Test Panels
6372516	Lateral Flow Test Devices
7041253	Sample Collection and Test Device
7300627	Test Sample Collection System

Contacts

Mr Howard Digby
Executive Chairman

ph: 0434987750

e: howarddigby@gmail.com

Dr Anton Uvarov
Director (after 20 November 2013)

ph: 0450662770

e: anton.uvarov@gmail.com

